Published in Clin Microbiol Infect on April 01, 2014
Outcome of mucormycosis after treatment: report of five cases. New Microbes New Infect (2014) 0.96
Necrotising fasciitis of the paranasal sinuses. Eur Arch Otorhinolaryngol (2016) 0.91
Galactomannan testing during mold-active prophylaxis. Clin Infect Dis (2014) 0.86
Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales. Antimicrob Agents Chemother (2015) 0.86
In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order. Antimicrob Agents Chemother (2015) 0.86
Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis. Antimicrob Agents Chemother (2014) 0.84
Invasive rhino-orbito-cerebral mucormycosis in a diabetic patient - the need for prompt treatment. Med Mycol Case Rep (2014) 0.84
Multimodal surgical and medical treatment for extensive rhinocerebral mucormycosis in an elderly diabetic patient: a case report and literature review. Case Rep Med (2014) 0.82
Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification. Eur J Clin Microbiol Infect Dis (2015) 0.81
Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections. Infect Drug Resist (2016) 0.81
Gastrointestinal Mucormycosis Resulting in a Catastrophic Outcome in an Immunocompetent Patient. Infect Dis Rep (2015) 0.81
Mucorales-Specific T Cells in Patients with Hematologic Malignancies. PLoS One (2016) 0.79
Invasive mold infections in solid organ transplant recipients. Scientifica (Cairo) (2014) 0.79
Clinical challenge: fatal mucormycotic osteomyelitis caused by Rhizopus microsporus despite aggressive multimodal treatment. BMC Infect Dis (2014) 0.78
Successful therapy of progressive rhino-orbital mucormycosis caused by Rhizopus arrhizus with combined and sequential antifungal therapy, surgery and hyperbaric therapy. Med Mycol Case Rep (2014) 0.78
Clinical features and outcome of mucormycosis. Interdiscip Perspect Infect Dis (2014) 0.77
Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infect Dis (2016) 0.77
Utility of frozen section analysis for fungal organisms in soft tissue wound debridement margin determination. Diagn Pathol (2015) 0.77
Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species. Antimicrob Agents Chemother (2015) 0.76
Therapeutic Drug Monitoring of Posaconazole: an Update. Curr Fungal Infect Rep (2016) 0.76
Current strategies against invasive fungal infections in patients with aplastic anemia, strong power and weak weapon, a case report and review of literature. Med Mycol Case Rep (2016) 0.75
Mucormycosis in a surgical defect masquerading as osteomyelitis: a case report and review of literature. Pan Afr Med J (2016) 0.75
Cutaneous mucormycosis in an immunocompromised patient: a case report. J Surg Case Rep (2017) 0.75
Diagnosis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-2). Turk J Haematol (2014) 0.75
An unusual ulcer: A case of cutaneous mucormycosis caused by Rhizopus oryzae. Med Mycol Case Rep (2014) 0.75
Combination Antifungal Therapy: A Review of Current Data. J Clin Med Res (2017) 0.75
Posttraumatic mucormycosis: a nationwide study in France and review of the literature. Medicine (Baltimore) (2014) 0.75
Retrospective Analysis on the Use of Amphotericin B Lipid Complex in Neutropenic Cancer Patients with Suspected Fungal Infections in Lebanon, a Single Center Experience and Review of International Guidelines. Front Med (Lausanne) (2016) 0.75
[Not Available]. Ann Burns Fire Disasters (2015) 0.75
Dual disseminated infection with Nocardia farcinica and Mucor in a patient with systemic lupus erythematosus: a case report. J Med Case Rep (2014) 0.75
Management of rhinomaxillary mucormycosis with Posaconazole in immunocompetent patients. J Oral Biol Craniofac Res (2016) 0.75
Disseminated mucormycosis (DM) after pneumonectomy: a case report. BMC Infect Dis (2016) 0.75
Granulocyte transfusions in the management of invasive fungal infections. Br J Haematol (2017) 0.75
Chronic pulmonary mucormycosis: an emerging fungal infection in diabetes mellitus. J Thorac Dis (2017) 0.75
Posaconazole liquid suspension in solid organ transplant recipients previously treated with voriconazole. Transpl Infect Dis (2015) 0.75
Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal Mucorales in an immunocompromised patient. Med Mycol Case Rep (2017) 0.75
Ventriculitis due to infection with Rhizopus arrhizus. Med Mycol Case Rep (2015) 0.75
Effective treatment of cerebral mucormycosis associated with brain surgery. Pediatr Infect Dis J (2015) 0.75
Molecular Identification of Mucor and Lichtheimia Species in Pure Cultures of Zygomycetes. Jundishapur J Microbiol (2016) 0.75
Recent developments in the management of invasive fungal infections in patients with oncohematological diseases. Ther Adv Hematol (2016) 0.75
A rare cause of ischemic gut: A case report. Int J Surg Case Rep (2016) 0.75
Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. BMC Infect Dis (2016) 0.75
Successful treatment of gastrointestinal mucormycosis in an adult with acute leukemia: case report and literature review. Curr Oncol (2017) 0.75
Erratum to, 'Outcome of mucormycosis after treatment: report of five cases'. New Microbes New Infect (2016) 0.75
Severe mycosis as a rare infection after a corn auger injury of the hand: a case report. Patient Saf Surg (2015) 0.75
Role of Antifungal Susceptibility Testing in Non-Aspergillus Invasive Mold Infections. J Clin Microbiol (2016) 0.75
kMucormicosys due to Saksenaea vasiformis in a dog. Med Mycol Case Rep (2017) 0.75
Mucormycosis of the Frontal Sinus: A Rare Case Report and Review. Ann Maxillofac Surg (2017) 0.75
[Infectious pulmonary diseases]. Pathologe (2014) 0.75
Marked peripheral eosinophilia due to prolonged administration of posaconazole. JMM Case Rep (2017) 0.75
Invasive gastric mucormycosis: A case report of a deadly complication in an immunocompromised patient after penetrating trauma. Int J Surg Case Rep (2017) 0.75
Higher In vitro Proliferation Rate of Rhizopus oryzae in Blood of Diabetic Individuals in Chronic Glycaemic Control Compared with Non-diabetic Individuals. Mycopathologia (2017) 0.75
Pulmonary mucormycosis: clinical features and outcomes. Infection (2017) 0.75
The spirochetal etiology of Lyme disease. N Engl J Med (1983) 21.59
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
The amino acid sequence of leghaemoglobin I from root nodules of broad bean (Vicia faba L.). FEBS Lett (1975) 9.08
Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med (1999) 8.80
Phytochrome A null mutants of Arabidopsis display a wild-type phenotype in white light. Plant Cell (1993) 7.51
Ecology. Synthesizing U.S. river restoration efforts. Science (2005) 7.26
Three abundance classes in HeLa cell messenger RNA. Nature (1974) 6.79
Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J (1986) 6.62
A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A (2004) 6.21
Cardiopulmonary resuscitation by chest compression alone or with mouth-to-mouth ventilation. N Engl J Med (2000) 5.65
Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A (2002) 5.33
Comparison study of broth macrodilution and microdilution antifungal susceptibility tests for the filamentous fungi. Antimicrob Agents Chemother (1996) 5.27
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect (2012) 4.56
Weekend hospitalization and additional risk of death: an analysis of inpatient data. J R Soc Med (2012) 3.77
Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest (2007) 3.58
Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A (1996) 3.54
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother (2007) 3.54
European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. Bone Marrow Transplant (2010) 3.46
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat (2011) 3.40
Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet (1998) 3.37
"White coat" versus "sustained" borderline hypertension in Tecumseh, Michigan. Hypertension (1990) 3.30
An association between viral genes and human oncogenic alterations: the adenovirus E1A induces the Ewing tumor fusion transcript EWS-FLI1. Nat Med (1999) 3.27
Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect (2004) 3.26
A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother (2003) 3.17
Biodiversity and systematics of basidiomycetous yeasts as determined by large-subunit rDNA D1/D2 domain sequence analysis. Int J Syst Evol Microbiol (2000) 3.14
Mediastinitis due to multiple resistant Corynebacterium xerosis. Clin Infect Dis (1993) 3.14
Microevolution of the direct repeat region of Mycobacterium tuberculosis: implications for interpretation of spoligotyping data. J Clin Microbiol (2002) 3.12
OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother (1993) 3.09
DNA-RNA hybridization in vast DNA excess. Nat New Biol (1971) 3.05
Dietary induced atherogenesis in swine. Morphology of the intima in prelesion stages. Am J Pathol (1979) 3.04
An anorexic lipid mediator regulated by feeding. Nature (2001) 2.94
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum (2009) 2.92
Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J Clin Microbiol (2001) 2.87
General primer-mediated PCR for detection of Aspergillus species. J Clin Microbiol (1994) 2.81
The Newbury Maternity Care Study: a randomized controlled trial to assess a policy of women holding their own obstetric records. Br J Obstet Gynaecol (1987) 2.78
Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) (1996) 2.72
Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med (2000) 2.70
Rapid, polymerase chain reaction-based identification assays for Candida species. J Clin Microbiol (1993) 2.70
Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates. J Clin Microbiol (1992) 2.69
Bacterial contamination of needles used for spinal and epidural anaesthesia. Br J Anaesth (1999) 2.69
Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect (2006) 2.67
Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community. J Clin Microbiol (2001) 2.67
Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin Microbiol Infect (2010) 2.63
Classification of drug-resistant tuberculosis in an epidemic area. Lancet (2000) 2.62
Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache (1999) 2.61
Aromatic-dependent Salmonella typhimurium as modified live vaccines for calves. Am J Vet Res (1984) 2.60
Sequence-based identification of Aspergillus, fusarium, and mucorales species in the clinical mycology laboratory: where are we and where should we go from here? J Clin Microbiol (2008) 2.57
Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol (2001) 2.53
Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol (1997) 2.53
Polyurethane internal ureteral stents in treatment of stone patients: morbidity related to indwelling times. J Urol (1991) 2.51
Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother (2004) 2.51
Impacted third molars. Br Dent J (1995) 2.49
Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet (1996) 2.45
Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology (2004) 2.41
Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect (2011) 2.38
Incidental lesions found on CT colonography: their nature and frequency. Br J Radiol (2005) 2.37
Unexpectedly high strain diversity of Mycobacterium tuberculosis in a high-incidence community. S Afr Med J (1996) 2.35
Accuracy of genomic selection methods in a standard data set of loblolly pine (Pinus taeda L.). Genetics (2012) 2.33
Transmission of a multidrug-resistant Mycobacterium tuberculosis strain resembling "strain W" among noninstitutionalized, human immunodeficiency virus-seronegative patients. J Infect Dis (1999) 2.31
Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol (2007) 2.29
Escherichia coli native valve endocarditis. Clin Microbiol Infect (2006) 2.28
Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis (1999) 2.28
Inoculum standardization for antifungal susceptibility testing of filamentous fungi pathogenic for humans. J Clin Microbiol (2001) 2.21
Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol (2010) 2.19
Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett (1997) 2.15
Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother (2013) 2.14
Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect (2009) 2.13
Aspergillus fumigatus pneumonia in neutropenic patients during therapy with fluconazole for infection due to Candida species. Clin Infect Dis (1993) 2.13
Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect (2004) 2.13
Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother (2001) 2.13
[Postanginal sepsis caused by Fusobacterium necrophorum: Lemierre syndrome]. Ned Tijdschr Geneeskd (1993) 2.11
The ultrastructure of transmissible murine colonic hyperplasia. Am J Pathol (1979) 2.11
Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur J Clin Microbiol Infect Dis (1991) 2.08
A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis (2012) 2.07
MRI of Hoffa's fat pad. Skeletal Radiol (2004) 2.07